Brief: Candel Therapeutics Q4 Net Income USD -29.496 Million
12/03/2026 12:05
Mar 12 (Reuters) - Candel Therapeutics Q4 operating expenses USD 15.752 million. Q4 income from operations USD -15.752 million vs. IBES estimate USD -13.9 million Q4 basic EPS USD -0.54
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec